Posted by Michael Wonder on 22 Nov 2016
European Commission approves Bristol-Myers Squibb’s Opdivo (nivolumab) for the treatment of adult patients with relapsed or refractory classical Hodgkin lymphoma after autologous stem cell transplant and treatment with brentuximab vedotin
22 November 2016 - First and only PD-1 inhibitor approved for a haematologic malignancy in the European Union.
Bristol-Myers Squibb Company today announced the European Commission approved Opdivo (nivolumab) for the treatment of adult patients with relapsed or refractory classical Hodgkin lymphoma (cHL) after autologous stem cell transplant (ASCT) and treatment with brentuximab vedotin.
This approval allows for the expanded marketing of Opdivo in relapsed or refractory cHL in all 28 Member States of the EU.
